Ida G. Lunde, Carsten Tschöpe, Johann Bauersachs, Faiez Zannad, Sanjay K Prasad, Gerasimos Filippatos, Xiao-Jun Du, Carlo G. Tocchetti, Piero Pollesello, Natalia López-Andrés, Wolfram-Hubertus Zimmermann, Theresa McDonagh, Manuel Mayr, Christoph Maack, Paul Ford, Stephane Heymans, Thomas Thum, Rudolf A. de Boer, Dirk L. Brutsaert, Alexander R. Lyon, John G.F. Cleland, Joost P.G. Sluijter, Frank R. Heinzel, Kenneth E. Lipson, Frank Ruschitzka, Gilles W. De Keulenaer, Merry L. Lindsey, Javier Díez, BOZEC, Erwan, HOMAGE (Heart Omics in Ageing consortium) - 305507 - INCOMING, Targeting cardiac fibrosis for heart failure treatment - FIBRO-TARGETS - - EC:FP7:HEALTH2013-09-01 - 2017-08-31 - 602904 - VALID, Hepatic and Cardiac Toxicity Systems modelling - HECATOS - - EC:FP7:HEALTH2013-10-01 - 2018-09-30 - 602156 - VALID, University Medical Center Groningen [Groningen] (UMCG), University of Antwerp (UA), Hannover Medical School [Hannover] (MHH), University of Glasgow, Center for Applied Medical Research [Plamplona] (CIMA), Universidad de Navarra [Pamplona] (UNAV), Clínica Universidad de Navarra [Pamplona], Baker Heart and Diabetes Institute (AUSTRALIA), Galecto Biotech, Charité Campus Virchow-Klinikum (CVK), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], FibroGen Inc., King's College Hospital (KCH), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], University of Oslo (UiO), Oslo University Hospital [Oslo], Royal Brompton Hospital, Orion Pharma, University of Naples Federico II = Università degli studi di Napoli Federico II, King‘s College London, University Medical Center [Utrecht], Institute of Molecular and Translational Therapeutic Strategies (IMTTS), German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), University Medical Center Göttingen (UMG), University hospital of Zurich [Zurich], University General Hospital ' Attikon ' [Athens, Greece], University of Mississippi Medical Center (UMMC), University of Würzburg = Universität Würzburg, University Hospital Wuerzburg / Universitätsklinikum Würzburg, Maastricht University [Maastricht], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), The Netherlands Heart Institute, R.A.d.B. is supported by the Netherlands Heart Foundation (CVON DOSIS, grant 2014-40, CVON SHE-PREDICTS-HF, grant 2017-21, and CVON RED-CVD, grant 2017-11), and the Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI, grant 917.13.350). J.B. is supported is supported by the Deutsche Forschungsgemeinschaft (DFG), Clinical Research Group 311 (KFO 311) ‘(Pre)terminal heart and lung failure: unloading and repair’ (DFG, TP1, BA 1742/9-1) and ‘MR-Focus’‘ (DFG BA 1742/8-1). J.S. has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (consolidator grant Evicare #725229) and by the Netherlands Heart Foundation (CVON-HUSTCARE). M.M. is a BHF Chair Holder (CH/16/3/32406), with BHF program grant support (RG/16/14/32397), and was awarded a BHF Special Project grant to participate in the ERA-CVD Translational Grant MacroERA. M.M. and T.T. are members of a network funded by the Foundation Leducq. C.G.T. is supported by a Federico II University/Ricerca di Ateneo grant. S.H. has received funding from the European Union Commission's Seventh Framework programme under grant agreement n. 305507 (HOMAGE), n. 602904 (FIBROTARGETS) and FP7-Health-2013-Innovations-1 n. 602156 (HECATOS), CVON2016-Early HFPEF, 2015-10, and CVON SHE-PREDICTS-HF, grant 2017-21. C.M. is supported by the DFG (Ma 2528/7-1, SFB 894, TRR-219) and the Federal Ministry of Education and Science (BMBF, 01EO150, CF.3, RC2)., European Project: 305507, European Project: 602904,EC:FP7:HEALTH,FP7-HEALTH-2013-INNOVATION-1,FIBRO-TARGETS(2013), European Project: 602156,EC:FP7:HEALTH,FP7-HEALTH-2013-INNOVATION-1,HECATOS(2013), de Boer, Rudolf A, De Keulenaer, Gille, Bauersachs, Johann, Brutsaert, Dirk, Cleland, John G, Diez, Javier, Du, Xiao-Jun, Ford, Paul, Heinzel, Frank R, Lipson, Kenneth E, Mcdonagh, Theresa, Lopez-Andres, Natalia, Lunde, Ida G, Lyon, Alexander R, Pollesello, Piero, Prasad, Sanjay K, Tocchetti, Carlo G, Mayr, Manuel, Sluijter, Joost P G, Thum, Thoma, Tschöpe, Carsten, Zannad, Faiez, Zimmermann, Wolfram-Hubertu, Ruschitzka, Frank, Filippatos, Gerasimo, Lindsey, Merry L, Maack, Christoph, Heymans, Stephane, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), RS: CARIM - R2.02 - Cardiomyopathy, RS: Carim - H02 Cardiomyopathy, University of Zurich, and Cardiovascular Centre (CVC)